Original article

Hepatitis C virus infection and spontaneous clearance in HTLV-1 and HIV co-infected patients in Salvador, Bahia, Brazil

Chloe Le Marchand a, Fabianna Bahia b, Kimberly Page c, Carlos Brites b,∗

a School of Medicine, University of California San Francisco, San Francisco, USA
b Department of Infectious Disease, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil
c Division of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico Health Sciences Center, Albuquerque, USA

ABSTRACT

Background: While 20–40% of patients with hepatitis C virus (HCV) monoinfection will spontaneously clear the virus, less is known regarding clearance with coinfections. HCV, human immunodeficiency virus (HIV), and human T-cell lymphotrophic virus 1 and 2 (HTLV-1/2) coinfec tion occurs due to shared routes of transmission and is prevalent in Brazil.

Objectives: To compare the proportion of patients who have spontaneously cleared HCV in patients with HCV monoinfection to patients coinfected by HCV/HIV, or HCV/HIV/HTLV-1.

Methods: Using medical records from two clinics in Salvador, Brazil, including demographic data and serological markers of HCV, HIV and HTLV-I/II, cross-sectional data was obtained from 197 patients. Patients who were anti-HCV positive and HCV RNA negative, and who did not receive HCV treatment were defined as having cleared infection.

Results: Nineteen patients (9.5%) showed evidence of spontaneous HCV clearance; with clearance in 9 of 108 (8.3%) patients in the HCV monoinfected group, 5 of 68 (7.4%) patients with HCV/HIV, and 5 of 21 (23.8%) patients with HCV/HIV/HTLV. Demographic data were not associated with HCV clearance status. Patients coinfected with both HIV and HTLV-1 had increased odds (5.50; 95% CI 1.00, 30.17) of spontaneous clearance of HCV compared with patients who were HIV negative or of unknown HIV status.

Conclusion: Our study found that patients coinfected with HIV and HTLV-1 were more likely to spontaneously clear hepatitis C virus than patients with HIV/HCV or HCV alone. The effects of HTLV coinfec tion on the immune response of such patients may be associated with these findings.
Background

The World Health Organization estimates that 180 million people, or 3% of the world’s population, are infected with hepatitis C virus (HCV) and that 130–170 million have chronic infection.1,2 HCV is tropic for hepatocytes and is a significant cause of morbidity, including cirrhosis and hepatocellular carcinoma, and mortality globally.3 HCV is a blood-borne pathogen, often in coinfection with other blood-borne infections, including human immunodeficiency virus (HIV) and human T-cell lymphotrophic virus-1/2 (HTLV-1/2). This is likely due to shared routes of transmission, such injection drug use (IDU), and in some contexts, contaminated blood products.4,5

Spontaneous resolution of HCV is of both scientific and clinical interest as knowledge of the time-course and factors associated can inform clinical care and prevention technologies, such as vaccine development. There is consistent evidence that about one quarter (25%) of HCV mono-infected individuals spontaneously resolve HCV infection.6,7 Several factors have been shown to be associated with spontaneous HCV clearance, including female sex, non-African ethnicity, jaundice at presentation, HLA type II alleles, and genetic factors, most strongly, IL28B allele variants.6–11 Prospective studies in acutely infected patients have shown that clearance of HCV infection is associated with a strong and broad host immune T-cell response.12–16

Little is known about frequency of spontaneous clearance and disease progression in individuals with triple infection: HCV, HIV and HTLV. HCV clearance in patients coinfected with HIV has been shown to be markedly reduced, with only 10–20% spontaneous clearing.17–19 Furthermore, HIV/HCV coinfected patients have significantly higher HCV viremia levels than in monoinfected patients and reduced response to anti-retroviral therapy.20,21 Much less is known about the natural history of HCV infection in the context of HTLV. HTLV-1 infection can cause adult T-cell leukemia/lymphoma (ATLL), which is a proliferation of CD4+ T-cells, and Th1 activation which is associated with neurological disease.22 HTLV replicates within T-cells and thereby compromises the cell-mediated immune response that may influence HCV clearance.23 Three studies of HCV/HTLV-1 coinfection, all of which were conducted in groups too small to demonstrate differences, have shown inconsistent results with respect to HCV clearance.24–26 Studies in Japan have found that HCV/HTLV-1 coinfected patients have, on average, increased HCV viremia,25 which is consistent with another study showing that coinfection had a multiplicative effect on the development of liver disease.27 In a recent study of patients infected with HCV/HIV/HTLV-1/2 in Brazil, we found that those with triple infection had on average lower ALT levels than patients coinfected with HIV/HCV, suggesting lower hepatic inflammation in the former group.28

Northeastern Brazil is a good location to study coinfection with these three viruses as HTLV-1 and HCV are endemic with a large population of asymptomatic carriers.29,30 HCV has been estimated to infect 1.1% of Brazilians.3 In the general population in Salvador, the prevalence of HTLV-1 and HIV is estimated at 1.35% and 0.55%, respectively.29,31 Data from very select populations in Brazil, including IDU, have found high infection rates for HCV, HTLV-1 and HIV: 70%, 22% and 44%, respectively.31,32 In this region, 80% of the population is of African descent,33 providing unique population in which to study spontaneous clearance, particularly as several studies have shown that black and racially diverse populations have lower HCV clearance rates.9,25,34

Objectives

To address the paucity of data on the impact of co-infection and triple infection with HCV, HIV and HTLV, we conducted a cross-sectional chart review. We compared the rates of HCV clearance in a cohort of mono- and co-infected patients with HCV, HCV/HIV and HCV/HIV/HTLV from two referral centers in Salvador, Brazil.

Study design

Study population

Cross-sectional data were abstracted from medical charts of patients infected with HCV, HIV/HCV, and HIV/HTLV/HCV in two outpatients services in Salvador, Bahia, Brazil: Hospital Universitario Professor Edgard Santos of Federal University of Bahia (HUPES) and Centro Estadual de Diagnosticos, Assistencia e Pesquisa (CEDAP), the central HIV/AIDS Referral Center in the state of Bahia. HUPES and CEDAP are both public institutions that serve patients infected with HIV and viral hepatitis in Bahia. Both CEDAP and the infectious disease outpatient clinic at HUPES see approximately 10,000 patients a year. Patients from CEDAP were primarily coinfected with HIV (including those with HCV, or triply infected with HCV, HIV and HTLV-1). HUPES patients were primarily HCV mono-infected, or HCV/HTLV coinfected.

Data collection

Patients’ records from 2008 to 2010 were reviewed; all patients who were anti-HCV positive and aged 18 or older were included. Sociodemographic data collected included age, sex, race, and where medical care was received. Age was categorized by five-year intervals. Race categories were those used in the medical charts, either white, meaning Caucasian descent, black, of African descent, or “pardo”, racially mixed descent. All data were abstracted twice by different research assistants, and then double entered into an EPIinfo 3.5.4 database (CDC, GA, USA). Patients were grouped as anti-HIV negative or unknown, anti-HIV positive and anti-HTLV negative or unknown and, finally, anti-HIV positive and anti-HTLV positive.

Laboratory tests

Laboratory tests results were obtained from medical records, including anti-HCV and HCV RNA, as well as HIV and HTLV results. The majority of laboratory testing was conducted in laboratories at the respective clinic or hospital where patients were seen. In brief, testing was done as follows: anti-HCV was tested for using enzyme immunoassay (EIA) (different
Table 1 – Demographic characteristics of HCV-positive participants overall and by HIV and HTLV status at two hospitals in Salvador, Brazil.

| Prevalence (characteristic) | Overall   | Anti-HIV (−)/unknown | Anti-HIV (+) and Anti-HTLV (−)/unknown | Anti-HTLV (+), Anti-HIV (+) | p-Value* |
|-----------------------------|-----------|-----------------------|----------------------------------------|-----------------------------|----------|
|                             | N (%)     | N (%)                 | N (%)                                  | N (%)                       |          |
| Overall                     | 197 (100) | 108 (54.8)            | 68 (34.5)                              | 21 (10.7)                   |          |
| Site                        |           |                       |                                        |                             |          |
| CEDAP                       | 82 (41.6) | 4 (4.8)               | 61 (74.4)                              | 17 (20.7)                   | <0.01    |
| HUPES                       | 115 (58.4)| 104 (90.4)            | 7 (6.1)                                | 4 (3.48)                    |          |
| Age                         |           |                       |                                        |                             |          |
| 40 and under                | 42 (21.8) | 16 (38.1)             | 22 (52.4)                              | 4 (9.5)                     | <0.01    |
| 41–45 years                 | 29 (15.0) | 13 (47.5)             | 12 (41.3)                              | 6 (20.7)                    |          |
| 46–50 years                 | 48 (24.9) | 19 (39.6)             | 21 (43.8)                              | 8 (16.7)                    |          |
| 51+ years                   | 74 (38.4) | 58 (78.4)             | 13 (17.6)                              | 3 (4.1)                     |          |
| Sex                         |           |                       |                                        |                             |          |
| Female                      | 80 (40.6) | 46 (57.5)             | 25 (31.3)                              | 9 (11.3)                    | 0.73     |
| Male                        | 117 (59.4)| 62 (53.0)             | 43 (36.8)                              | 12 (10.3)                   |          |
| Race                        |           |                       |                                        |                             |          |
| White                       | 16 (8.1)  | 15 (93.8)             | 1 (6.3)                                | 0 (0)                       | <0.01    |
| Pardo (Mixed)               | 57 (18.8) | 29 (78.4)             | 5 (13.6)                               | 3 (18.6)                    |          |
| Black                       | 16 (8.2)  | 13 (81.3)             | 3 (18.8)                               | 0 (0)                       |          |
| Missing                     | 128 (65.0)| 51 (39.8)             | 59 (46.1)                              | 18 (14.1)                   |          |

*Fischer's Exact test include missing data.

manufacturers, but most commonly Elisa Meia AxSYM tests (Abbott ELISA Kit, USA); HIV testing was determined using two enzyme immunoassays (EIA) (HIV-1 QT; Bio Manguinhos, Rapid Check HIV 1 and 2) and confirmed by western blot (Genelabs, Singapore). HTLV-1 was tested by EIA (Abbott Biomerix Kit; USA), and confirmed by western blot (Genelabs, Singapore). HCV RNA was tested for using HCV Amplicor 2.0; Roche Diagnostics, Pleasanton, CA) with lower limit of detection of 50 UI/mL (120 cp/mL). Results negative for HCV RNA were classified as being aviremic.

Statistical analyses

The main outcome variable of our study was HCV clearance. Patients who were anti-HCV positive and HCV RNA negative, and with no record of HCV treatment were classified as having spontaneously cleared HCV. Patients who were HCV RNA positive or who received treatment were categorized as having HCV infection. Covariates of interest were co-infection with HIV and/or HTLV-1. Participants were divided into three groups: patients with negative or unknown HIV status and negative or unknown HTLV status (Group 1), patients with positive HIV status and negative or unknown HTLV status (Group 2) and, finally, patients with positive HIV and HTLV-1 status (Group 3). There were no patients with positive HTLV status whose HIV status was unknown. Univariate associations between groups by sociodemographic and clinical factors were assessed using Fisher’s exact tests. Firth's logistic regression was used to assess factors independently associated with HCV clearance by coинфекtion status, adjusting for potential confounders including age, site and sex. Odds ratios (OR), adjusted odds ratios (AOR) and 95% confidence intervals (CI), were estimated. Race was excluded from multivariate analyses due to the significant amount of missing data and large number of participants who were classified as mixed race. All analyses were conducted using STATA for Mac statistic software package version 11.0 and the Firth logit module with distribution date: 2008/07/14.

Ethical review

The study protocol was reviewed and approved by the Research Ethics Committee of the Secretary of Health of the State of Bahia (Comite de Etica em Pesquisa da Secretaria de Saude do Estado da Bahia – CEP SESAB) and the UCSF Committee on Human Research. Informed consent for this retrospective chart review was waived.

Results

The study team screened 575 patients for inclusion in the study; 357 participants were excluded because they were not anti-HCV positive. Medical charts from 218 patients were reviewed, of which 21 were excluded due to missing HCV RNA status, leaving 197 records for analyses. Over half of the patients (n = 115, 58.4%) received care at HUPES, the remaining at CEDAP. The majority of patients were male (n = 117 or 59.4%); mean age was 48.5 years (SD 9.67). Information on race/ethnicity was available for 69 patients, among those, 23.2% were White, 53.6% as “Pardo” and 23.2% as Black (Table 1). Overall, 9.5% (n = 19) patients had evidence of spontaneous HCV clearance. There were significant differences between the HIV/HTLV groupings by clinical site, principally since the infectious disease clinic at HUPES saw few HIV infected patients. HCV monoinfected patients were
There were significantly more male than female patients, which was consistent with other reports. However, a higher percentage of female patients were diagnosed with HTLV infection in our study, which we believe to be related to the告语 that they may be more likely to seek hospital care due to their reproductive health. We also found a higher percentage of female patients in the age group 41–45 years,

Discussion

In this study of HCV infected patients in Salvador, Brazil, we found that patients who were coinfected with HTLV had a greater likelihood of spontaneous clearance of HCV infection overall. Additionally, those with HIV and HTLV infection had an increased clearance: almost a quarter (23.9%) of patients who had evidence of HCV infection and who were also coinfected with the two other viruses demonstrated evidence of spontaneous clearance compared to 8% of HIV-positive/HTLV-negative patients. Our results suggest the possibility that HTLV infection may have immune effects that enhance responses to HCV infection. In a previous study we showed that cultured mononuclear cells from these HIV/HTLV coinfected patients had a higher spontaneous production of IL-1, γ-interferon, and lower production of IL-4. In addition, in a recent work, we also detected significantly higher serum levels of eight proinflammatory cytokines (IL-1b, IL-2, FGF, γ-IFN, IP-10, MIP-1α, MIP-1β, TNF-α) in patients coinfected with HIV-HCV and HTLV, in comparison to HIV-HCV coinfected individuals. There was also a strong association between higher levels of these cytokines and sustained virological response, among patients treated for HCV infection. We do not know the temporal order in which patients were infected, however if HTLV infected patients develop higher HCV viremia in acute infection, as suggested by other studies, this could also be associated with immune responses that increase HCV clearance. Taken together, these results suggest that this profile of immune response is a likely result of HTLV coinfecion, potentially contributing to the higher rate of spontaneous HCV clearance seen in patients in this study. We believe these new data can point to new directions for immunology studies of successful HCV infection responses. A better understanding of such

Table 2 – Bivariate and multivariate associations of HIV/HTLV co-infection status and demographic characteristics with spontaneous HCV clearance in patients at two hospitals in Salvador, Brazil.

| Coinfection status | HCV spontaneous clearance | OR (95% CI) | p-Value | Adjusted OR* (95% CI) | p-Value |
|--------------------|---------------------------|-------------|---------|-----------------------|---------|
| HIV−/unknown       | 9/108 (8.3)               | 1           |         | 1                     |         |
| HIV+ and HTLV−/unknown | 5/68 (7.4)       | 0.91 (0.30, 2.71) | 0.86     | 1.61 (0.29, 8.97)     | 0.58    |
| HIV+ and HTLV+     | 5/21 (23.8)              | 3.49 (1.08, 11.27) | 0.037    | 5.50 (1.00, 30.17)    | 0.049   |
| HIV                 |                           |             |         |                       |         |
| Negative            | 2/44 (4.6)               | 1           |         |                       |         |
| Positive            | 10/89 (11.2)             | 2.25 (0.54, 9.37) | 0.27     |                       |         |
| Unknown             | 7/64 (10.9)              | 2.22 (0.50, 9.79) | 0.29     |                       |         |
| HTLV                |                           |             |         |                       |         |
| Negative            | 5/76 (6.6)               | 1           |         |                       |         |
| Positive            | 5/24 (20.8)              | 3.67 (1.02, 13.2) | 0.047    | 3.58 (1.00, 12.90)    | 0.051   |
| Unknown             | 9/97 (9.3)               | 1.40 (0.47, 4.17) | 0.56     | 1.24 (0.22, 4.64)     | 0.75    |
| Age                 |                           |             |         |                       |         |
| 40 and under        | 4/42 (9.5)               | 1           |         |                       |         |
| 41–45 years        | 4/29 (13.8)              | 1.51 (0.37, 6.12) | 0.56     |                       |         |
| 46–50 years        | 4/48 (8.3)               | 0.87 (0.22, 3.43) | 0.84     |                       |         |
| 51–80 years        | 6/74 (8.1)               | 0.81 (0.23, 2.88) | 0.75     |                       |         |
| Sex                 |                           |             |         |                       |         |
| Female              | 9/80 (11.3)              | 1           |         |                       |         |
| Male                | 11/117 (9.6)             | 0.74 (0.29, 1.86) | 0.52     |                       |         |
| Race                |                           |             |         |                       |         |
| Branco (White)      | 1/16 (6.3)               | 1           |         |                       |         |
| Pardo (Mixed)       | 1/37 (2.7)               | 0.42 (0.04, 4.41) | 0.47     |                       |         |
| Negro (Black)       | 3/16 (18.8)              | 2.68 (0.35, 20.75) | 0.35     |                       |         |
| Missing             | 14/128 (10.9)            | 1.31 (0.22, 7.63) | 0.77     |                       |         |
| Site                |                           |             |         |                       |         |
| CEDAP               | 8/82 (9.7)               | 1           |         |                       |         |
| HUPES               | 11/115 (9.6)             | 0.96 (0.38, 2.46) | 0.94     |                       |         |

a Adjusted for: sex, age, and site using Firth’s logistic regression.
mechanisms could be translated in future improvements on treatment for patients coinfected with HIV and HCV.

Our study had many limitations including a small sample size that restricted our statistical power resulting in large confidence intervals with results of nominal significance. We chose to use Firth logistic regression in order to adjust for important covariates, such as sex, and due to our small sample size with separation. We also had a significant amount of missing data that we were unable to obtain from the medical charts, particularly in regards to race, as well as coinfections. In regard to the missing data for race, the data that was collected reflected the racial distribution found in other studies conducted in the state of Bahia as well as census data.\textsuperscript{39-41} Given the large amount of missing data and that the majority of participants were of mixed racial background, this variable did not add meaningful information to our multivariate model. With respect to missing coinfection data, we conducted further sensitivity analyses examining less conservative groupings assuming patients with unknown HIV status or HTLV status were positive for HIV and HTLV. These analyses also showed similar significant findings: patients with HIV and HTLV had increased odds of spontaneous clearance of HCV.

We used two different clinics to obtain our study population, which could also have introduced selection or information bias if clinical data was collected with systematic differences, which we could not assess. We did not identify if patients were infected with HTLV-1 or II; however HTLV-1 is present in 95% to 98% of all infections in Salvador, so it is likely the prevalent infection in this analysis.\textsuperscript{39} We were also not able to assess genetic associations between interferon-lambda 3 (IFNL3, previously called IL28B), and which is known to be associated with HCV clearance.\textsuperscript{42,43} Our sampling allowed us to capture the majority of patients with recent HCV infections receiving care in the state of Bahia; however, our study has inherent selection bias as HIV infected patients received more comprehensive and regular testing for HCV than non-HIV infected patients. Finally, this was a cross-sectional study using historical data, which limits our ability to fully control for all confounders and determine causality.

Very little has been published on the role of coinfections in patients with HCV. Despite its limitations, our study is the first to examine spontaneous HCV clearance in patients infected with HTLV and HIV, a more complex and potentially realistic scenario than examining these diseases individually as many of these infections coexist and are transmitted via similar routes. The present findings suggest that HTLV coinfected patients may have a positive effect on the spontaneous clearance of HCV, especially in HIV+ coinfected patients. The available research on the immune response in this population indicates that the production of proinflammatory cytokines is upregulated in coinfected individuals, potentially contributing to HCV clearance. Taken together, these results provide a new insight on the role of specific immune response in HCV infection and advance understanding of HTLV and HCV infections.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors would like to acknowledge Alexandre Azevedo Ziomkowski, Adriana Fonseca Oliveira de Melo, Tassia Maria Oliveira dos Santos for their invaluable help with data collection.

References

1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20–9.
2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl. 1:74–81.
3. Perez JF, Alter MJ. The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol. 2006;44:441–3.
4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.
5. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:56–9.
6. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41.
7. Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection. Hepatology. 2013 [e-pub Aug 3].
8. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200:1216–26.
9. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.
10. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2008;461:798–801.
11. Wang CC, Krantz E, Klargquist J, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474–82.
12. Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673–81.
13. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol. 2004;58:391–424.
14. Elliot LN, Lloyd AR, Ziegler JB, Ffrench RA. Protective immunity against hepatitis C virus infection. Immunol Cell Biol. 2006;84:239–49.
15. Folgori A, Spada E, Pezzanner M, et al. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut. 2006;55:1012–9.
16. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42:104–12.
17. Grebely J, Raffa JD, Lai C, Kradjen M, Conway B, Tyn dall MW. Factors associated with spontaneous clearance of hepatitis C.
virus among illicit drug users. Can J Gastroenterol. 2007;21:447–51.
18. Daar ES, Lynn H, Donfeld S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr. 2001;26:466–72.
19. shores NJ, Maida I, Soriano V, Nunez M. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol. 2008;49:323–8.
20. Matthews GV, Dore GJ. HIV and hepatitis C co-infection. J Gastroenterol Hepatol. 2008;23:1000–8.
21. Matthews-Greer JM, Caldito GC, Adley SD, et al. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immunol. 2001;8:690-4.
22. Yoshida M, Kiyokawa T, Watanabe T, Hattori S, Fujisawa J, Seiki M. Nakahara memorial lecture. Human T-cell leukemia virus type I: molecular biology and its implications in adult T-cell leukemia. Princess Takamatsu Symp. 1984;15:39–47.
23. Eckels DD, Wang H, Bian TH, Tabatabai N, Gill JC. Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev. 2000;174:90–7.
24. Bentrem DJ, McGovern EE, Hammerskold ML, Edlich RF. Human T-cell lymphotropic virus type-I (HTLV-I) retrovirus and human disease. J Emerg Med. 1994;12:825–32.
25. Hisada M, Chatterjee N, Zhang M, Batts RS, Goedert JJ. Increased hepatitis C virus load among injection drug users infected with human immunodeficiency virus and human T lymphotropic virus type II. J Infect Dis. 2003;188:891–7.
26. Toro C, Bassani S, Rios P, Jimenez V, Camino N, Soriano V. Influence of HTLV-II infection on hepatitis C virus replication in HIV-positive patients. J Clin Virol. 2005;32:338–9.
27. Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis. 2000;181:35–41.
28. Bahia F, Novais V, Evans J, et al. The impact of human T-cell lymphotropic virus type I infection in clinic and immunologic outcomes in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr. 2011;57 Suppl. 3:S202–7.
29. Dourado I, Alcantara LC, Barreto ML, da Gloria Teixeira M, Galvao-Castro B. HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr. 2003;34:527–31.
30. Moxoto I, Bon-Sorte N, Nunes C, et al. [Sociodemographic, epidemiological and behavioral profile of women infected with HTLV-1 in Salvador, Bahia, an endemic area for HTLV]. Rev Soc Bras Med Trop. 2007;40:37–41.
31. Dourado I, Milroy CA, Mello MA, et al. HIV-1 seroprevalence in the general population of Salvador, Bahia State, Northeast Brazil. Cad Saude Publica. 2007;23:25–32.
32. Oliveira ML, Bastos FI, Telles PR, et al. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Braz J Med Biol Res. 1999;32:1107–14.
33. Azevedo ES, Fortuna CM, Silva KM, et al. Spread and diversity of human populations in Bahia, Brazil. Hum Biol. 1982;54:329–41.
34. Cursino-Santos JR, Donadi EA, Martinelli AL, Louzada-Junior P, Martinez-Rossi NM. Evolution of hepatitis C virus infection under host factor influence in an ethnically complex population. Liver Int. 2007;27:1371–8.
35. Abrahao MH, Lima RG, Netto E, Brites C. Short communication: human lymphotropic virus type 1 co-infection modulates the synthesis of cytokines by peripheral blood mononuclear cells from HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2012;28:806–8.
36. Bahia F, Abrahao MH, Netto EM, Bozza P, Brites C. HTLV-1 infection modulates the immune response in HIV-HCV coinfected patients and may increase spontaneous HCV clearance. In: 16th international conference on human retrovirology: HTLV and related viruses. 2013 [abstract O1-2277].
37. Hajariadad B, Grady B, Page K, et al., on behalf of the InC3 Study Group. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLOS ONE. 2015 [in press].
38. Liu L, Fisher BE, Thomas DL, Cox AI, Ray SC. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology. 2012;55:1684–91.
39. Moreira ED Jr, Ribeiro TT, Swanson P, et al. Seroepidemiology of human T-cell lymphotropic virus type I/II in northeastern Brazil. J Acquir Immune Defic Syndr. 1993;6:959–63.
40. Moreira ED Jr, Lbo CF, Diamant A, Nicolosi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61:431–6.
41. IBGE – Instituto Brasileiro de Geografia e Estatística, PNAD – Pesquisa Nacional por Amostra de Domicílios. 2000. Available from: http://www.ibge.gov.br/estadosat/perfil.php?sigla=ba [accessed 01.11.13].
42. Booth D, George J. Loss of function of the new interferon IFN-lambda4 may confer protection from hepatitis C. Nat Genet. 2013;45:119–20.
43. Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12:408–14.